Gastrointestinal Risk Assessment in the Patients Taking Nonsteroidal Anti-inflammarory Drugs for Lumbar Spinal Disease (비스테로이드성 소염진통제를 복용중인 요추질환 환자에서의 위장관계 위험도 평가)

Byung Ho Lee (이병호); Seong-Hwan Moon (문성환); 신병준; 김동준; 이재철; 석경수; 박예수; 김기원; CHO KYU JUNG (조규정); 신근영; Min Suk Ko (고민석)

Gastrointestinal Risk Assessment in the Patients Taking Nonsteroidal Anti-inflammarory Drugs for Lumbar Spinal Disease

Journal of Korean Society of Spine Surgery
Abbr : J Kor Spine Sur
2011, 18(4), pp.239~245
Publisher : Korean Society Of Spine Surgery
Research Area : Medicine and Pharmacy > Orthopedic Surgery

Byung Ho Lee ¹, Seong-Hwan Moon ¹, 신병준 ², 김동준 ³, 이재철 ², 석경수 ⁴, 박예수 ⁵, 김기원 ⁶, CHO KYU JUNG ⁷, 신근영 ¹, Min Suk Ko ¹

¹연세대학교
²순천향대학교
³이화여자대학교
⁴경희대학교
⁵한양대학교
⁶가톨릭대학교
⁷인하대학교

Accredited

ABSTRACT

Study Design: A cross-section observational study. Objectives: To evaluate the current prescription patterns of non-steroidal anti-inflammatory drugs (NSAIDs) and gastrointestinal (GI) risk assessment in patients with lumbar spine disease. Summary of Literature Review: NSAIDs are commonly prescribed medications for lumbar spine disease patients. Since the rate of GI complication varies for each patient, identification of individual GI risks is a prerequisite to prevent such a complication. There are few reports about the GI risks in patients with lumbar spine disease who take NSAIDs. Materials and Methods: 2264 patients with lumbar degenerative spondylopathy who were taking NSAIDs were enrolled from May 2010 to September 2010. The Standardized Calculator of Risk for Event (SCORE) was used to measure patients’ GI risk factors. NSAID prescription patterns and GI protective agents were also investigated. Results: Being aged over 65 (1098 patients; 48.5%) and the presence of GI side-effects from NSAIDs (896 patients;,39.6%) were the most common risk factors. 31.9% and 5.8% percent of patients belonged to each of the high risk and the very high risk groups in GI risk factor analysis. The total prescription rate of gastroprotectants was 91.7% for all patients. However, the prescription rate of selective COX-2 inhibitors in the high risk group was low, and in 54.8% of patients who took COX-2 inhibitors there was GI discomfort. Conclusions: The prescription pattern of GI protective agents was not correlated with GI symptoms. Therefore, physicians should consider NSAID prescription based on the GI risk factors of individual patients.

KEYWORDS

Lumbar spine, NSAIDs, Gastrointestinal, Risk

Citation status

* References for papers published after 2025 are currently being built.

[journal] van Tulder MW / 2000 / Nonsteroidal anti-inflammatory drugs for low back pain: a systematic review within the framework of the Cochrane Collaboration Back Review Group / Spine (Phila Pa 1976) 25 : 2501~2513

[journal] Chung JY / 2007 / Effectof Tramadol/Acetaminophen Combination Drug in Acute Pain After Spinal Surgery / J Korean Soc Spine Surg 14 : 137~143

[journal] Garcia Rodriguez LA / 1994 / Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs / Lancet 343 : 769~772

[journal] Laine L / 2006 / GI risk and risk factors of NSAIDs / J Cardiovasc Pharmacol 47(1 Suppl) : 60~66

[journal] Singh G / 2001 / Arthritis, Rheumatism and Aging Medical Information System Post-Marketing Surveillance Program / J Rheumatol 28 : 1174~1179

[journal] Schlansky B / 2009 / Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy / J Gastroenterol 44(19 Suppl) : 44~52

[journal] Fries JF / 1991 / Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models / Am J Med 91 : 213~222

[journal] Fries JF / 2004 / The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis / Arthritis Rheum 50 : 2433~2440

[journal] Tramèr MR / 2000 / Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use / Pain 85 : 169~182

[journal] Hernández-Díaz S / 2000 / Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s / Arch Intern Med 160 : 2093~2099

[journal] Bull SA / 2002 / Relationship of clinical factors to the use of Cox-2 selective NSAIDs within an arthritis population in a large HMO / J Manag Care Pharm 8 : 252~258

[journal] Lazzaroni M / 1999 / -steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors / Ital J Gastroenterol Hepatol 31(1 Suppl) : 73~78

[book] Daniel WW / 1999 / Biostatistics: A foundation for analysis in the health science 7thed / John Wiley & Sons

[journal] Wolfe MM / 1999 / Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs / N Engl J Med 340 : 1888~1899

[journal] Lapane KL / 2001 / The effect of nonsteroidal anti-inflammatory drugs on the use of gastroprotective medication in people with arthritis / Am J Manag Care 7 : 402~408

[journal] Griffin MR / 1998 / Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury / Am J Med 30 : 23~29

[journal] Logan R / 2001 / ABC of the upper gastrointestinal tract: implications of dyspepsia for the NHS / BMJ 323 : 675~677

[journal] 이성훈 / 2011 / Prescription Pattern of NSAIDs and the Prevalence of NSAID-induced Gastrointestinal Risk Factors of Orthopaedic Patients in Clinical Practice in Korea / Journal of Korean Medical Science / 대한의학회 26(4) : 561~567

[journal] Helsper CW / 2009 / Trends and determinants of adequate gastroprotection in patients chronically using NSAIDs / Pharmacoepidemiology and drug safety 18 : 800~806

[journal] Chancellor JV / 2001 / Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland / PharmacoEconomics 19(1 Suppl) : 59~75

[journal] Burke TA / 2001 / A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis / PharmacoEconomics 19(1 Suppl) : 33~47

[journal] Langman MJ / 1999 / Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs / JAMA 282 : 1929~1933

[journal] Silverstein FE / 1995 / Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial / Ann Intern Med 123 : 241~249

KJCKorea
Journal Central

Journal of Korean Society of Spine Surgery 2025 KCI Impact Factor : 0.1